The correlation between serum levels of IGFBP5 and disease phenotypes that indicate progression of NAFLD to NASH is informative and could potentially point to a biomarker of disease progression, but it should be noted that the serum concentration of IGFBP5 does not reflect liver-tissue specific IGFBP5 expression. The gene discussed is IGFBP5; the disease is metabolic dysfunction-associated steatotic liver disease.